US research roundup: Allstate, Caribou Biosciences, Zscaler
CRBU•Analysts revised ratings and price targets on US-listed companies Wednesday. HSBC raised Allstate to buy from hold, RBC cut Caribou Biosciences to sector perform from outperform and lowered its target to $1 from $10, while Jefferies raised Zscaler’s target to $250 from $220.
1. Highlighted analyst moves
HSBC raised Allstate to buy from hold while cutting its price target to $266 from $282. RBC cut Caribou Biosciences to sector perform from outperform and lowered its target price to $1 from $10. Jefferies raised Zscaler’s target price to $250 from $220, and JPMorgan raised it to $245 from $215.
2. Other research actions
Marvell Technology drew several positive changes: Jefferies raised its target to $450 from $325, JPMorgan raised its target to $360 from $305, and TD Cowen upgraded the stock to buy from hold and raised its target to $350 from $245. Analysts also cut Arrivent Biopharma targets, with four firms setting targets between $18 and $29, down from prior targets between $42 and $45.
